What Is NAD+ Therapy? Benefits & Clinical Evidence
TL;DR: NAD+ therapy replenishes nicotinamide adenine dinucleotide, a molecule essential for cellular energy and repair that declines by approximately 50% between ages 40 and 60. According to a 2020 systematic review in Experimental Gerontology, NAD+ precursors show promise for age-related concerns, with patients in clinical trials reporting improvements in energy, mental clarity, and physical function.
Your cells rely on thousands of molecular processes every second. One molecule stands out as particularly vital: NAD+, or nicotinamide adenine dinucleotide. As you age, your NAD+ levels naturally decline, and researchers believe this drop may contribute to many hallmarks of aging.
So what is NAD+ therapy, and why are physicians increasingly interested in its potential? This guide explores the science, reported benefits, and clinical evidence behind NAD+ supplementation.
Medically reviewed by the Vea Health Clinical Team
What Is NAD+ Therapy?
NAD+ therapy involves supplementing with precursors that your body converts into NAD+, a coenzyme present in every living cell. NAD+ plays essential roles in energy production, DNA repair, and cellular signaling. Clinical approaches typically use precursors like nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), which research suggests can effectively raise NAD+ levels in human tissues.
NAD+ acts as a critical cofactor for enzymes called sirtuins and PARPs. These enzymes regulate cellular health, stress response, and longevity pathways. Without adequate NAD+, these protective mechanisms can't function optimally.
The therapy typically comes in oral form, though some clinics offer intravenous administration. Your physician-led protocol at Vea Health will determine the most appropriate delivery method based on your individual health profile and wellness goals.
How Does NAD+ Work in Your Body?
NAD+ functions as a shuttle for electrons during cellular respiration, the process that converts food into usable energy. According to research published in Nature Medicine, NAD+ biosynthesis is evolutionarily conserved and essential for maintaining cellular metabolism. When NAD+ levels drop, cells struggle to produce ATP, the energy currency your body runs on.
Beyond energy production, NAD+ serves as a substrate for enzymes that repair damaged DNA and regulate gene expression. Every time your DNA sustains damage from oxidative stress, UV exposure, or normal cellular processes, repair enzymes consume NAD+ to fix the breaks. A 2020 systematic review by Braidy and Liu found that NAD+ depletion impairs these repair mechanisms, potentially accelerating cellular aging.
Your body can synthesize NAD+ through several pathways. The salvage pathway recycles nicotinamide, while the de novo pathway builds NAD+ from the amino acid tryptophan. However, both pathways become less efficient with age, leading to the progressive decline in tissue NAD+ levels observed in older adults.
What Are the Reported Benefits of NAD+ Therapy?
Patients have reported improvements in several areas when following NAD+ precursor protocols. A 2024 randomized controlled trial in Nature Communications examined nicotinamide riboside in people with peripheral artery disease. While the primary endpoint focused on walking performance, the study demonstrated that oral NR successfully increased bioavailable NAD+ levels in human subjects.
Clinical experience and patient reports suggest potential benefits in these areas:
Energy and physical performance: Many patients begin noticing changes in stamina and exercise recovery within 2-4 weeks of consistent use
Mental clarity and focus: Evidence supports NAD+'s role in neuronal health and cognitive function
Sleep quality: NAD+ influences circadian rhythm regulation through its interaction with clock genes
Metabolic function: Research indicates NAD+ may support healthy blood sugar management and cellular metabolism
Cellular repair processes: Studies suggest NAD+ precursors may enhance DNA repair capacity and stress resilience
It's important to understand that individual responses vary. Your personalized protocol considers your unique health profile, and your Vea Health physician monitors your progress to optimize outcomes.
Who Might Consider NAD+ Therapy?
Adults experiencing age-related changes in energy, cognition, or metabolic health often explore NAD+ supplementation as part of their wellness journey. The therapy appeals particularly to individuals between 35 and 65 who prioritize proactive health optimization rather than waiting for concerns to become significant.
You might be a candidate if you're noticing:
Decreased energy levels that don't respond to sleep or lifestyle changes
Reduced mental sharpness or processing speed
Slower recovery from exercise or physical activity
Interest in evidence-based anti-aging protocols
Concern about metabolic health as you age
NAD+ therapy isn't appropriate for everyone. Your physician will review your medical history, current medications, and health goals before recommending this approach. Certain conditions or medications may influence whether NAD+ precursors fit into your protocol.
The Role of Baseline Testing
While direct NAD+ measurement isn't widely available in clinical practice, your provider may order baseline metabolic panels and other biomarkers. These help establish your starting point and provide objective data to track changes during your journey.
Some patients combine NAD+ therapy with other evidence-based interventions. Your Vea Health protocol may integrate nutritional optimization, targeted peptides, or hormone balance strategies depending on your specific needs.
What Do Studies Show About NAD+ Supplementation?
Clinical research on NAD+ precursors has expanded significantly over the past five years, with multiple randomized controlled trials now published in peer-reviewed journals. A 2023 safety trial published in Nature Communications evaluated high-dose nicotinamide riboside (up to 3000 mg daily) in Parkinson's disease patients. The study found that these doses were well-tolerated, with NAD+ levels in peripheral blood mononuclear cells increasing in a dose-dependent manner.
The evidence base includes several key findings. Research by Poyan Mehr and colleagues in 2018 revealed that de novo NAD+ biosynthesis becomes impaired during acute kidney injury in humans, suggesting NAD+ metabolism plays a direct role in human disease states. This finding supports the biological plausibility of NAD+ replenishment strategies.
A 2024 systematic review in the Journal of Alzheimer's Disease examined NAD+ precursors for cognitive health. The authors noted that while preclinical data appears promising, human studies remain limited in scope. They emphasized that NAD+ supplementation represents a metabolic approach that targets fundamental cellular processes rather than isolated pathways.
"NAD+ acts as an important cofactor and substrate for a multitude of biological processes including energy production, DNA repair, gene expression, and calcium-dependent secondary messenger signaling," according to the 2020 systematic review by Braidy and Liu in Experimental Gerontology.
The current evidence suggests NAD+ precursors can effectively raise cellular NAD+ levels in humans. Whether these biochemical changes translate to meaningful clinical outcomes across diverse populations requires additional long-term studies. The field continues to evolve rapidly, with new trials examining specific health applications.
Safety Profile and Considerations
Published trials generally report favorable safety profiles for NAD+ precursors at standard doses. The most commonly reported effects include mild gastrointestinal discomfort in some individuals, particularly at higher doses.
Your physician will consider potential interactions with your current medications. NAD+ influences numerous enzymatic pathways, so comprehensive medical oversight ensures your protocol remains safe and appropriate as your health needs evolve.
How Does NAD+ Therapy Fit Into Your Wellness Strategy?
NAD+ supplementation works best as part of a comprehensive approach to healthy aging and cellular optimization. Research suggests that lifestyle factors like exercise, caloric intake, and sleep quality also influence NAD+ metabolism. Your body's NAD+ levels respond to these inputs through complex regulatory networks.
At Vea Health, physicians view NAD+ therapy within the broader context of your health goals. Are you focused on maintaining cognitive performance as you age? Optimizing metabolic function? Supporting physical resilience and recovery? Your specific objectives shape your personalized protocol.
The timing and dosing of NAD+ precursors may matter. Some evidence suggests taking supplements earlier in the day aligns better with your body's natural circadian rhythms. Your physician will provide specific guidance based on your protocol design.
Many patients appreciate the evidence-based nature of NAD+ therapy. Rather than relying on anecdotal claims, this approach rests on peer-reviewed research and clinical trials conducted at major academic medical centers. That scientific foundation provides confidence as you invest in your long-term health.
Ready to explore whether NAD+ therapy fits your wellness goals?
Our physician-led team creates personalized protocols based on your unique health profile and optimization objectives. Start your consultation to discuss evidence-based options for cellular health and healthy aging.
Frequently Asked Questions
How long does it take to notice changes with NAD+ therapy?
Response timelines vary by individual, but many patients report noticing shifts in energy or mental clarity within 2-4 weeks of consistent use. Objective biomarker changes may take 8-12 weeks to become apparent. Your physician will establish realistic expectations based on your specific protocol and health status.
Can I take NAD+ precursors with other supplements?
NAD+ precursors generally combine well with other evidence-based interventions. However, you should discuss your complete supplement regimen with your physician. Some combinations may offer synergistic benefits, while others require timing adjustments to optimize absorption and effectiveness.
What's the difference between NR and NMN?
Both nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) serve as NAD+ precursors, but they enter the NAD+ biosynthesis pathway at slightly different points. Current clinical trials have primarily studied NR, which has more published safety data in humans. Your physician will recommend the most appropriate option for your protocol.
Do NAD+ levels naturally decline with age?
Yes. Research consistently shows that tissue NAD+ levels decrease progressively with aging. Studies suggest approximately a 50% reduction between ages 40 and 60, though the rate varies by tissue type and individual factors. This decline may contribute to age-related changes in cellular function and metabolic health.
Is NAD+ therapy the same as NAD+ IV infusions?
No. While both approaches aim to support NAD+ levels, they differ in delivery method and evidence base. Oral NAD+ precursors (like NR or NMN) have been studied in multiple randomized controlled trials. Direct NAD+ infusions have less clinical research supporting their use. Your Vea Health physician focuses on evidence-based approaches with established safety profiles.
References
Braidy N, Liu Y. NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis. Exp Gerontol. 2020;132:110831. PMID: 31917996
McDermott M, et al. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Nat Commun. 2024;15:4926. PMID: 38871717
Berven H, et al. NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease. Nat Commun. 2023;14:8037. PMID: 38016950
Poyan Mehr A, et al. De novo NAD+ biosynthetic impairment in acute kidney injury in humans. Nat Med. 2018;24(9):1351-1359. PMID: 30127395
Alghamdi M, Braidy N. Supplementation with NAD+ Precursors for Treating Alzheimer's Disease: A Metabolic Approach. J Alzheimers Dis. 2024. PMID: 39422945
Source Studies:
Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Pat... — Journal of the American College of Cardiology (2020)
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. — The New England journal of medicine (2020)
NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis. — Experimental gerontology (2020)
Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality.
Treatments are prescribed at provider discretion. Individual results may vary.